Gland Pharma Ltd

{"amount":18}

{"actualRevenue":17427900000,"estimateRevenue":16763000000,"revenueSurprise":664900000,"revenueSurprisePercent":3.966473781542684,"actualEPS":22.23,"estimateEPS":15.143575,"surprise":7.086425,"surprisePercent":46.79492788195654}

{"actualRevenue":16953630000,"estimateRevenue":16350000000,"revenueSurprise":603630000,"revenueSurprisePercent":3.691926605504587,"actualEPS":17.35,"estimateEPS":15.9032,"surprise":1.446800000000001,"surprisePercent":9.097540117712168}

{"actualRevenue":14868750000,"estimateRevenue":16029000000,"revenueSurprise":-1160250000,"revenueSurprisePercent":-7.238442822384428,"actualEPS":11.15,"estimateEPS":14.031175,"surprise":-2.881175000000001,"surprisePercent":-20.53409639606092}

{"actualRevenue":15056220000,"estimateRevenue":15771000000,"revenueSurprise":-714780000,"revenueSurprisePercent":-4.532242723987065,"actualEPS":13.08,"estimateEPS":13.4724,"surprise":-0.3924000000000003,"surprisePercent":-2.912621359223303}

{"description":"Gland Pharma jumped 11% after Q4 FY26 net profit rose 97% YoY to Rs 366.7 crore, revenue grew 22% to Rs 1,742.8 crore, and the board recommended Rs 20/share final dividend.","url":"https://economictimes.indiatimes.com/markets/stocks/news/gland-pharma-shares-jump-11-as-q4-profit-soars-97-yoy-co-announces-rs-20/share-final-dividend/articleshow/131166671.cms","sentiment":"Positive","domain":"Indiatimes"}

{"description":"Gland Pharma rose 14.3% to a 52-week high after Q4 profit jumped 86.2% to ₹467.6 crore, revenue grew 22.3%, and Kotak upgraded it to 'add' with a ₹2,075 target.","url":"https://www.cnbctv18.com/market/gland-pharma-share-price-q4-result-reaction-gains-most-in-nearly-three-years-kotak-upgrade-target-upside-ws-el-19907799.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Gland Pharma shares surged 16% to a 52-week high after Q4 results, with Elara Capital and Motilal Oswal retaining Buy calls, boosting sentiment.","url":"https://www.business-standard.com/markets/mutual-fund/gland-pharma-shares-jump-16-to-52-week-high-on-q4-analysts-retain-buy-126051800177_1.html","sentiment":"Positive","domain":"Business Standard"}

{"description":"Gland Pharma surged after Q4 FY26 net profit rose 96.62% to Rs 366.7 crore and sales climbed 22.31% to Rs 1,742.8 crore, boosting investor sentiment.","url":"https://www.business-standard.com/markets/capital-market-news/gland-pharma-spurts-as-q4-pat-jumps-97-yoy-to-rs-367-crore-126051800187_1.html","sentiment":"Positive","domain":"Business Standard"}

{"description":"Gland Pharma's consolidated net profit rose 96.57% in the March 2026 quarter; full-year profit climbed 47.07% to Rs 1,027.32 crore and sales increased 14.50% to Rs 6,430.65 crore.","url":"https://www.business-standard.com/markets/capital-market-news/gland-pharma-consolidated-net-profit-rises-96-57-in-the-march-2026-quarter-126051501350_1.html","sentiment":"Positive","domain":"Business Standard"}